期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 32, 期 6, 页码 1011-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2018.07.015
关键词
Epithelial ovarian carcinoma; Treatment; Low-grade serous carcinoma; Endometrioid carcinoma; Mucinous carcinoma; Small cell carcinoma of the ovary; Clear cell carcinoma; Carcinosarcoma
Traditionally, the management of epithelial ovarian cancer has been approached using a one-size-fits-all mentality. This strategy does not acknowledge the differences in epidemiology and clinical behavior of many of the histologic and molecular subgroups of ovarian cancer, specifically the rare histologies. While cytoreductive surgery followed by adjuvant platinum and taxane-based chemotherapy is the mainstay of primary treatment of epithelial ovarian cancer as a group, further investigation of novel therapeutics is critical for improving outcomes of these rare histologies. This article focuses on the management of non-high grade serous histologies of ovarian cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据